High dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients

Journal of Cystic Fibrosis

Volumn 9, Issue 4, 2010, Pages 280-283

  Zobell, Jeffery T ^a,b   Ampofo, Krow ^c   Cash, Jared ^a   Korgenski, Kent ^c,d   Chatfield, Barbara A ^b  

^a PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^b Intermountain Cystic Fibrosis Adult Center   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d Intermountain Healthcare   (United States)

Author keywords

Antibiotics; Cystic fibrosis; Pediatrics; Safety; Ticarcillin clavulanate

Indexed keywords

CREATININE; TIMENTIN; ANTIINFECTIVE AGENT; CLAVULANIC ACID; TICARCILLIN; TICARCILLIN-CLAVULANIC ACID;

ADOLESCENT; ADULT; ANAPHYLAXIS; ANTIBIOTIC SENSITIVITY; ARTHRALGIA; ARTICLE; BURKHOLDERIA CEPACIA; CHILD; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEMATURIA; HUMAN; INFANT; LEUKOCYTE COUNT; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEWBORN; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; SIDE EFFECT; STENOTROPHOMONAS MALTOPHILIA; THROMBOCYTE COUNT; TREATMENT DURATION; DISEASE COURSE; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG APPROVAL; PRESCHOOL CHILD;

ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CLAVULANIC ACIDS; CREATININE; CYSTIC FIBROSIS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG APPROVAL; HUMANS; INFANT; LEUKOCYTE COUNT; LIVER FUNCTION TESTS; PLATELET COUNT; RETROSPECTIVE STUDIES; TICARCILLIN;

EID: 77953915742     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2010.04.003     Document Type: Article

References (20)

1. Timentin® Approved Package labeling. GlaxoSmithKline, 2009.
2. Flume P.A., Mogayzel P.J., Robinson K.A., Goss C.H., Rosenblatt R.L., Kuhn R.J., et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Resp Crit Care Med. 2009, 180:802-808.
3. Primary Children's Medical Center Microbiology Laboratory. Cumulative Antimicrobial Susceptibility Test (Antibiogram) Data Report. 2010.
4. Crowcroft N.S., Roveaux O., Monnet D.I., Mertens R. Methicillin-resistant Staphylococcus aureus and antimicrobial use in Belgian hospitals. Infect Control Hosp Epidemiol. 1999, 20(1):31-36.
5. Nadesalingam K., Conway S.P., Denton M. Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis. J Cyst Fibros. 2005, 4(1):49-52.
6. Moller N.E., Hoiby N. Antibiotic treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. Scand J Infect Dis Suppl. 1981, 29:87-91.
7. Reed M.D., Stern R.C., Myers C.M., Klinger JD, Yamashita TS, Blumer JL Therapeutic evaluation of piperacillin for acute pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol Mar-Apr 1987, 3(2):101-109.
8. Red Book, Thomson Healthcare; 2007 Ed.
9. Gibson R.L., Burns J.L., Ramsey B.W. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Resp Crit Care Med. 2003, 168:918-951.
10. Microbiology and Infectious Disease in Cystic Fibrosis. Cystic Fibrosis Foundation Consensus Conference. 1994; Volume V, Section I.
11. Ervin F.R., Bullock W.E. Clinical and pharmacological studies of ticarcillin in gram-negative infections. Antimicrob Agents Chemother. 1976, 9(1):94-101.
12. Nelson J.D., Kusmiesz H., Shelton S., Woodman E. Clinical pharmacology and efficacy of ticarcillin in infants and children. Pediatrics. 1978, 61:858-863.
13. Conway S.P., Miller M.G., Ramsden C., Littlewood JM. Intensive treatment of pseudomonas chest infection in cystic fibrosis: a comparison of tobramycin and ticarcillin, and netilimicin and ticarcillin. Acta Paediatr Scand. 1985, 74:107-113.
14. Horrevorts A.M., de Witte J., Degener J.E., Dzoljic-Danilovic G, Hop WC, Driessen O, et al. Tobramycin in patients with cystic fibrosis. Adjustment in dosing interval for effective treatment. Chest. 1987, 92:844-848.
15. Schaad U.C., Desgrandchamps D., Kraemer R. Antimicrobial therapy of pseudomonas pulmonary exacerbations in cystic fibrosis. Acta Paediatr Scand. 1986, 75:128-138.
16. De Groot R., Hack B.D., Weber A., Chaffin D., Ramsey B., Smith A.L. Pharmacokinetics of ticarcillin in patients with cystic fibrosis: a controlled prospective study. Clin Pharmacol Ther. 1990, 47:73-78.
17. Nelson Textbook of Pediatrics 18th Edition by Kliegman, Behrman, Jenson, and Stanton; 2007, Elsevier, Inc. 1119, 1182.
18. Red book 29th edition. Report of the Committee on Infectious Diseases 2009, The American Academy of Pediatrics.
19. Pediatric dosage handbook 2010, Lexi-Comp, Inc.
20. http://faculty.vassar.edu/lowry/utest.html.